Valproate and neuroprotection

Journal of Clinical Neuroscience

Volumn 9, Issue 5, 2002, Pages 508-514

  Vajda, F J E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; GABAPENTIN; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ABSENCE; EPILEPSY; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MIGRAINE; NEUROPROTECTION; NEUROTRANSMISSION; PRIORITY JOURNAL; REVIEW; SEIZURE;

EID: 0036746137     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1054/jocn.2002.1133     Document Type: Review

References (72)

1. Chadwick D. Valproate in the treatment of partial epilepsies. Epilepsia 1994: 35 (Suppl. 3); 596-598.
2. Bladin PF. 2002 Personal communication.
3. Vajda FJE. Neuroprotection and neurodegenerative disease. J Clin Neurosci 2002; 9: 4-8.
4. Manji HK, McNamara RM, Chen G, Lenox RH. Signalling pathways in the brain: cellular transduction of mood stabilisation in the treatment of manic-depressive illness. ANZ J Psych 1999; 33: S65-83.
5. Hardy J, Gwinn-Hardy K. Genetic classification of primary neurodegenerative diseases. Science 1998; 282: 1075-1078.
6. Singh R, Gardner RJ, Crossland KM, Scheffer IE, Berkovic SF. Chromosomal abnormalities in epilepsy: a review for clinicians and gene hunters. Epilepsia 2001; 43: 127-140.
7. Shinnar S, Berg AT. Does antiepileptic drug therapy prevent the development of 'chronic' epilepsy? Epilepsia 1996: 37: 701-708.
8. Silver JM, Shin C, McNamara JO. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy. Ann Neurol 1991; 29: 356-363.
9. Löscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999; 58: 31-59.
10. Hernandez TD. Preventing post-traumatic epilepsy after brain injury: weighing the costs and benefits of anticonvulsant prophylaxis. Trends Pharmacol Sci 1997; 18: 59-62.
11. Eadie MJ. Can anticonvulsant drug therapy 'cure' epilepsy? CNS Drugs 2001; 15: 679-690.
12. First Seizure Trial Group (FIRST Group). Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. Neurology 1993; 43: 478-483.
13. Gudmundsson G. Epilepsy in Iceland. A clinical and epidemiological investigation. Acta Neurol Scand 1966; 43 (Suppl. 25): 4-124.
14. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta analysis of controlled trials. Epilepsia 2001; 42: 515-524.
15. Meldrum BS. Why and when are seizures bad for the brain? Trends Pharmacol Sci 2001; 22: 445-446.
16. Sutula TP, Pitkänen A. More evidence for seizure-induced neuron loss: is hippocampal sclerosis both cause and effect of epilepsy? Neurology 2001; 57:169-170.
17. Fuerst D, Shah J, Kupsky WJ et al. Volumetric MRI. pathological, and neuropsychological progression in hippocampal sclerosis. Neurology 2001;57:184-188.
18. Briellmann RS, Newton MR. Wellard RM, Jackson GD. Hippocampal sclerosis following brief generalised seizures in adulthood. Neurology 2001; 57: 315-317.
19. Schulz R, Ebner A. Prolonged febrile convulsions and medial temporal lobe epilepsy in an identical twin. Neurology 2001; 57: 318-320.
20. Hassel B, Iversen EG, Gjerstad L. Taubøll E. Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate. J Neurochem 2001; 77: 1285-1292.
21. 2+-valproate in cultured cerebellar neurons. Funct Neurol 1995; 10: 121-130.
22. Beghi E. The use of anticonvulsants in neurological conditions other than epilepsy. CNS Drugs 1999; 11: 61-82.
23. Cutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia 1997; 17: 93-100.
24. Balfour JA, Bryson HM. Valproic acid - a review of its pharmacology and therapeutic potential in indications other than epilepsy. CNS Drugs 1994; 2: 144-173.
25. Petty F. GABA and mood disorders: a brief review and hypothesis. J Affect Disord 1995; 34: 275-281.
26. Shen DD and Levy RH. Valproate. In: Antiepileptic Drugs Pharmacology and Therapeutics. Eadie MJ, Vajda FJE (eds). Heidelberg: Springer, 1999, 359-373.
27. Farielllo RG, Varasi M, Smith MC. Valproic acid: mechanisms of action. In: Antiepileptic drugs. Levy RH, Mattson RH, Meldrum BS (eds). New York: 4th edn. Raven Press, 1995, 567-575.
28. Wikinski SI, Acosta GB, Rubio MC. Valproic acid differs in its in vitro effect on glutamic acid decarboxylase activity in neonatal and adult rat brain. Gen Pharmacol 1996; 27: 635-638.
29. Löscher W, Vetter M. Drug-induced changes in GABA content of nerve endings in I I rat brain regions: correlation to pharmacological effects. Neurosci Lett 1984; 47: 325-331.
30. Ticku MK, Davis WC. Effects of valproic acid on H-diazepam and H-dihydropicrotoxin in binding sites at the benzodiazepine-GABA receptor-ionophore complex. Brain Res 1981; 223: 218-222.
31. Gale K. Progression and generalization of seizure discharge: anatomical and neurochemical substrates. Epilepsia 1988; 29: S15-S34.
32. Rohlsfs A, Rundfeldt C, Koch R, Löscher W. A comparison of the effects of valproate and its major active metabolite E-2-en-valproate on single unit activity of substantia nigra pars reticulata neurons in rats. J Pharmacol Exp Ther 1996; 277: 1305-1341.
33. Zhang Y-F, Gibbs JW, Coulter DA. Anticonvulsant drug effects on spontaneous thalamocortical rhythms in vitro: valproic acid, clonazepam, and α-methyl-α-phenylsuccinimide. Epilepsy Res 1996; 23: 37-53.
34. Zeise ML, Kasparaow S, Zieglgansberger W. Valproate suppresses N-methyl-D-aspartate evoked, transient depolarisations in the rat neocortex in vitro. Brain Res 1991; 544: 345-348.
35. Gean P-W, Hung C-C, Hung C-R, Tsai J-J. Valproic acid suppresses the synaptic response mediated by the NM DA receptors in rat amygdalar slices. Brain Res Bull 1994; 33: 333-336.
36. Ko GY-PL, Brown-Croyts LM, Teyler TJ. The effects of anticonvulsant drugs on NMDA-EPSP, AMPA-DPSP, and GABA-IPSP in the rat hippocampus. Brain Res Bull 1997; 42: 297-302.
37. McLean MJ, MacDonald RL. Sodium valproate, but not ethosuximide. produces use and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986; 237: 1001-1011.
38. +] in the hippocampal slice. Brain Res 1986; 386: 1-11.
39. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39: 5-17.
40. Somerville E. Antiepileptic drug therapy and seizure aggravation. Epilepsy Society of Australia, Annual Scientific meeting, Adelaide, 1999.
41. Jeavons PM, Clark JE, Mahesgwari MC. Treatment of generalised epilepsies of childhood and adolescence with sodium valproate. Dev Med Child Neurol 1977; 19: 9-25.
42. Mireles R, Leppik IE. Valproate and clonazepam comedication in patients with intractable epilepsy. Epilepsia 1985: 26: 122-126.
43. Yang L, Benardo LS. Valproate prevents epileptiform activity after trauma in an in vitro model in neocortical slices. Epilepsia 2000: 41: 1507-1513.
44. Schmutz M, Klebs K. Baltzer V. Inhibition or enhancement of kindling evolution by antiepileptics. J Neural Trans 1988; 72: 245-257.
45. Wada JA, Sato M, Wake A, Green JR, Troupin AS. Prophylactic effects of phenytoin, phenobarbital, and carbamazepine examined in kindling cat preparations. Arch Neurol 1976: 33: 426-434.
46. Gueldry S, Rochette L, Bralet J. Comparison of the effects of valproate, ethosuximide, phenytoin, and pentobarbital on cerebral energy metabolism in the rat. Epilepsia 1987; 28: 160-168.
47. Schürks M, Wiegand F, Diener H-C. Neuroprotektion: eine neue therapeutische Option in der Epilepsie-therapie? Akt Neurol 2001: 28:326-332.
48. Manji HK. Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000a; 48: 740-754.
49. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000b; 5: 578-593.
50. Manji HK, Moore GJ, Chen G. Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilisers. Br J Psychiatry 2001, 178 (suppl 41): s107-s119.
51. Moore GJ, Bebchuk JM, Wilds IB. Chen G, Manji HK, Menji HK. Lithium-induced increase in human brain grey matter. Lancet 2000; 356: 1241-1242.
52. Chen G, Zeng W-Z. Yuan P-X et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999; 72: 879-882.
53. Motohashi N. Valproate for the treatment of psychiatric disorders. Jpn J Neuropsychopharmacol 2001; 21: 47-53.
54. Spiegel AM, Weinstein LS, Shenker AJ. Abnormalities of G protein-coupled signal transduction pathways in human disease. Clin Investigation 1993; 92: 1119-1125.
55. +. Eur J Biochem 1999; 266: 886-891.
56. Lenox RH, McNamara RK, Watterson JM, Watson DG. Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? J Clin Psychiatry 1996; 57 (suppl 13): 23-31.
57. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain Psychopharmacologia 2001; 158: 100-106.
58. Hua LV, Green M, Wong A, Warsh JJ, Li PP. Tetraspan protein CD151: a common target of mood stabilizing drugs? Neuropsychopharmacology 2001; 25: 729-736.
59. Li R. El-Mallahk RS. A novel evidence of different mechanisms of lithium and valproatc neuroprotective action on human SY5Y neuroblastoma cells: caspase-3 dependency. Neurosci Lett 2000; 294: 147-150.
60. Chen B, Wang JF, Young LT. B. Chronic valproate treatment increases expression of endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus. Biol Psychiatry 2000; 48: 658-664.
61. Murphy KJ, Fox GB. Foley AG et al. Pentyl-4-yn-valproic acid enhances both spatial and avoidance learning, and attenuates age-related NCAM-mediated neuroplastic decline within the rat medial temporal lobe. J Neurochem 2001; 78: 704-714.
62. Eriksson PS, Perfilieva E, Bjork-Eriksson T et al. Neurogenesis in the adult human hippocampus. Nat Med 1998; 4: 1313-1317.
63. Kempermann G, Gage FH. Experience-dependent regulation of adult hippocampal neurogenesis: effects of long-term stimulation and stimulus withdrawal. Hippocampus 1999;9:321-332.
64. Subramanium S. Structuring biological data - lessons from cellular signalling. Australian Neuroscience Informatics Symposium held at Howard Florey Institute. University of Melbourne. February 2002.
65. Tsai G. Coyle JT. N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 1995; 46: 531-540.
66. Andrews RJ. Neuroprotection for the new milleneum. Matchmaking pharmacology and technology. Ann NY Acad Sci 1999; 939: 114-125.
67. Jenner P, Olanow CWT. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996; 46 (Suppl. 3): S161-170.
68. Robberecht W. Oxidative stress in amyotrophic lateral sclerosis. J Neurol 2000; 247 (Suppl. 1): S11-S16.
69. Mattson MP, Pedersen WA. Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease. Int J Devl Neurosei 1998; 16: 737-753.
70. Blass J, Poirier J. Pathophysiology of the Alzheimer syndrome. In: Clinical diagnosis and management of Alzheimer's Disease. Gauthier S (ed.). London: Martin Dunitz. 1996. 17-31.
71. 2+ deregulation and cytoskeletal pathology. Neurobiol Aging 1995; 16: 187-198.
72. Eadie MJ. 2002 Personal communication.